Patient Support Services Contact Us
Image: Coherus Investors



A fully integrated biopharmaceutical company with a robust pipeline across multiple therapeutic areas.

Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system.

In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

REDWOOD CITY, Calif. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences , Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson . He had been a director of the Company since January 2021 and had previously served as external
- UDENYCA ® On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial - Coherus plans to seek U.S. marketing authorization for the  UDENYCA ®   OBI in 2022 REDWOOD CITY, Calif. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
REDWOOD CITY, Calif. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) today announced that positive results from the pivotal COLUMBUS-AMD clinical trial evaluating and comparing the efficacy and safety between CHS-201 and Lucentis® (ranibizumab) in the
FDA has set a target action date of August 2, 2022 for the CHS-201 BLA REDWOOD CITY, Calif. , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) today announced the United States Food and Drug Administration (FDA) has accepted for review the 351(k) Biologics
Events & Presentations
There are currently no events scheduled.